Sophisticated new genetic tests face an uncertain future — unless they can win clear-cut approval from regulators, insurers and, most importantly, doctors. Virginia Gewin reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Opinion: The US Food and Drug Administration perspective on cancer biomarker development
A regulatory perspective on in vitro diagnostics
Three barriers to innovative diagnostics
Related external links
Rights and permissions
About this article
Cite this article
Crunch time for multiple-gene tests. Nature 445, 354–355 (2007). https://doi.org/10.1038/445354a
Published:
Issue Date:
DOI: https://doi.org/10.1038/445354a
This article is cited by
-
Nutzung von Markersystemen in der Behandlung des Harnblasenkarzinoms
Der Urologe (2011)
